TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06559839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibulocortical Stimulation
Description: 50cc of cold water (4℃) irrigated to the right external ear canal, at 1-2 cc/second, with the patient laying supine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibulocortical Stimulation
Description: 50cc of cold water (4℃) irrigated to the right external ear canal, at 1-2 cc/second, with the patient laying supine.
Study: NCT05737732

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Circadian Ineffective Lightning (CIL)
Description: Participants will receive lower lighting levels in the morning (lighting with A spectrum of 300k, \<50lux to the eye level between 7:00am and 10:00am) and the same lighting levels throughout the rest of the day.
Study: NCT06107829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine Oral Capsule
Description: Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
Study: NCT06004804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Seeks to help individuals achieve present moment awareness, self-compassion, and acceptance of chronic pain. It will use techniques such as the body scan, grounding, mindful breathing, mindful walking, loving kindness, and compassionate breathing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
Study: NCT04333966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Social Networking Site Parent Based Intervention
Description: Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Parents in the active control condition will receive an emailed copy of the Surgeon General's Call to Action: A Guide for Families.
Study: NCT05514665

Intervention type: DEVICE
Intervention: Diffuse Optical Tomography
Description: Neonates once hemodynamically stable will undergo diffuse optical tomography measurements of functional brain connectivity at the bedside within 3-7 days after birth.
Study: NCT06488781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given in place of other two active drugs
Study: NCT05718362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ayres Sensory Integration Therapy
Description: It is an intervention method whose effectiveness is questioned. It is a therapy program applied according to Ayres Sensory Integration Fidelity Measure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Program
Description: These are the activities created for the participants (both intervention and control groups) and to be done in the home environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Program
Description: These are the activities created for the participants (both intervention and control groups) and to be done in the home environment.
Study: NCT06018883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Vitamin C 900 mg/day, three times a day, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Nab paclitaxel
Description: Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
Study: NCT06008002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: M-TAPA block
Description: ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (0.3 ml/kg , %0.25 bupivacaine) will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EXORA block
Description: Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg , %0.25 bupivacaine) will be performed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Study: NCT06195579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transforming the Intense Child Workbook (Glasser, 2016)
Description: The NHA was delivered in a guided self-help format, using the Transforming the Intense Child workbook (Glasser, 2016) and weekly phone calls.
Study: NCT05572281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon Oral Capsule
Description: No additional information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon Oral Capsule
Description: No additional information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon Oral Suspension
Description: No additional information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon Oral Suspension
Description: No additional information
Study: NCT06563362

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalation of irradiated volume
Description: De-escalation of elective clinical target volumes as recommended by a model-based approach
Study: NCT06559345

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TMLI
Description: The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study: NCT06119763

Intervention type: DIAGNOSTIC_TEST
Intervention: anti dfs70 antibodies
Description: blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre

Intervention type: DIAGNOSTIC_TEST
Intervention: anti dfs70 antibodies
Description: blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre
Study: NCT05755282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-market foam alcohol-based hand sanitizer #1
Description: Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-market foam alcohol-based hand sanitizer #1
Description: Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-market foam alcohol-based hand sanitizer #2
Description: Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-market foam alcohol-based hand sanitizer #2
Description: Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
Study: NCT05457413

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Bariatric surgery
Study: NCT05433857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacteol forte capsules
Description: probiotic Lacteol Forte® capsules (5 billion heat-killed Lactobacillus LB, corresponding to lactobacillus delbruekii and lactobacillus fermentum) Two capsules are To be taken once daily
Study: NCT04730466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological rehabilitation
Description: The intervention can be carried out in the research unit or in the Parkinson's association. Each session will consist of a series of cognitive stimulation tasks aimed at improving attention, perception and processing speed. These tasks will be applied through the NeuronUp cognitive neurorehabilitation platform to achieve maximum homogeneity and objectivity in their application. The program is programmed and is identical for all patients. Performing tasks through the platform allows us to objectively record the performance of each patient in all tasks.
Study: NCT06502340

Intervention type: DIAGNOSTIC_TEST
Intervention: high sensitive troponin I
Description: high-sensitive Troponin I levels
Study: NCT06242613

Intervention type: PROCEDURE
Intervention: Robot-Assisted Gastrectomy
Description: Gastrectomy performed with a robotic system.

Intervention type: PROCEDURE
Intervention: Laparoscopic Gastrectomy
Description: Gastrectomy performed with conventional laparoscopic approach.
Study: NCT05487248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample Collection
Description: For subjects receiving treatments with a 2- or 4-weekly schedule, blood samples for ctDNA testing will be collected at the following timepoints:~* Before treatment start (day 1)~* 2 weeks after treatment start (day 15)~* 4 weeks after treatment start (day 29)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e., at the same time of each imaging tumour assessment)~For subjects receiving treatments with a 3-weekly schedule, blood samples for ctDNA testing will be collected at the following timepoints:~* Before treatment start (day 1)~* 3 weeks after treatment start (day 22)~* 6 weeks after treatment start (day 43)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e., at the same time of each imaging tumour assessment)
Study: NCT04377945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1, JM-010 component Group A
Description: JM-010 component Group A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1, JM-010 component Group B
Description: JM-010 component Group B
Study: NCT05929937

Intervention type: DRUG
Group type: OTHER
Intervention: Opioids
Description: Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)

Intervention type: OTHER
Group type: OTHER
Intervention: No opioids
Description: Standard of care, patients will not receive a prescription for opioids.
Study: NCT06188702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095035
Description: S095035 will be taken orally once daily in 28-day cycle.
Study: NCT06046586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and information
Description: Emotional and technical support. Information about the long-term effects of cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and information
Description: Emotional and technical support. Information about the long-term effects of cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and information
Description: Emotional and technical support. Information about the long-term effects of cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and information
Description: Emotional and technical support. Information about the long-term effects of cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and information
Description: Emotional and technical support. Information about the long-term effects of cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and information
Description: Emotional and technical support. Information about the long-term effects of cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and information
Description: Emotional and technical support. Information about the long-term effects of cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and information
Description: Emotional and technical support. Information about the long-term effects of cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: Behavioral activation with existential themes and emphasis on values and relationships.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: Behavioral activation with existential themes and emphasis on values and relationships.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: Behavioral activation with existential themes and emphasis on values and relationships.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: Behavioral activation with existential themes and emphasis on values and relationships.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic exposure with mindfulness training
Description: Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic exposure with mindfulness training
Description: Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
Study: NCT04377945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1, JM-010 component Group C
Description: JM-010 component Group C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 1, Placebo Group
Description: Placebo Group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2, JM-010 combination Group A
Description: JM-010 combination Group A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2, JM-010 combination Group B
Description: JM-010 combination Group B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2, JM-010 component Group C
Description: JM-010 component Group C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 2, Placebo Group
Description: Placebo Group
Study: NCT06046586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic exposure with mindfulness training
Description: Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic exposure with mindfulness training
Description: Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
Study: NCT04946318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CSJ117
Description: CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CSJ117
Description: CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CSJ117
Description: CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaled once daily for 12 or 24 weeks. Delivered via Concept1 device.
Study: NCT05187117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPABLE Family - Open Label Pilot
Description: As in CAPABLE (NA_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations for cognitive decline will be made on a per-client basis as part of the open-label pilot. Topics of adaptations include problem areas addresses, care partner involvement, length/frequency of visits, types of assessments and questions asked, and brainstorming/action planning structure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPABLE Family - Randomized Control Trial
Description: As in CAPABLE (NA_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAPABLE Family - Randomized Control Trial
Description: As in CAPABLE (NA_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
Study: NCT06008002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Study: NCT06025370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone Position
Description: All healthy volunteers will be positioned in prone position, on a bed equipped with a mapping pressure system.~The volunteers will spend 5 minutes in each of the positions corresponding to the study groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Position
Description: All healthy volunteers will be positioned in prone position, on a bed equipped with a mapping pressure system.~The volunteers will spend 5 minutes in each of the positions corresponding to the study groups.
Study: NCT04944225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Reduction Strategy
Description: The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
Study: NCT03903471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22G-ProCore Endobronchial Ultrasound Needle
Description: EchoTip Procore® Endobronchial HD Ultrasound Biopsy Needle, COOK

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22G-Standard Endobronchial Ultrasound Needle
Description: EchoTip® Ultra Endobronchial High Definition Ultrasound Needle, COOK
Study: NCT06046586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of health behaviors
Description: An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of health behaviors
Description: An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of health behaviors
Description: An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of health behaviors
Description: An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
Study: NCT06003179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning chemo at different doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning chemo at different doses